Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

Pharmaceuticals : Displaying 4-13 of 33


Six Novartis Executives Charged In Illegal Drug Rebate Scheme In South Korea
by Richard SmallteacherSpecial to CorpWatch
August 11th, 2016
Six executives of Swiss pharmaceutical giant Novartis have been indicted in a South Korean bribery scandal. The indictments follow similar charges in China, Turkey and the U.S. and allegations of falsifying drug trial data in Japan. Korean prosecutors have recommended that Novartis sales be suspended for six months.

Gilead Avoided $10 Billion In Taxes On Over Priced Hepatitis C Drugs
by Richard SmallteacherSpecial to CorpWatch
July 13th, 2016
Gilead Sciences Inc., a California based pharmaceutical company, has avoided paying $10 billion in taxes by moving its patents to Ireland. This is despite the fact that one of its most profitable drugs was developed with U.S. taxpayer money, according to a new report from Americans for Tax Fairness.

Ovarian Cancer Victims Win Talcum Powder Lawsuits Against Johnson & Johnson
by Richard SmallteacherCorpWatch Blog
April 4th, 2016
Johnson & Johnson has been sued by over 1,200 women who blame the company's talcum powder products for their ovarian cancer. Not only are U.S. courts beginning to agree with them, juries have started to award victims millions of dollars in compensation.

Drugs Tested By GVK Biosciences Banned From European Union
by Pratap ChatterjeeCorpWatch Blog
July 27th, 2015
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules.

DaVita Pays $895 Million To Settle Kidney Treatment Fraud Claims
by Richard SmallteacherCorpWatch Blog
May 14th, 2015
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.

Actavis Sued To Stop Forced Switch To New Alzheimer's Drug
by Richard SmallteacherCorpWatch Blog
September 16th, 2014
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.

Gilead Sciences Under Investigation for Over Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Big Pharma Abandons New Tuberculosis Drug Research
by Fatima HansiaCorpWatch Blog
April 1st, 2014
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Bayer CEO Says Drugs Developed For “Western Patients Who Can Afford It”
by Pratap ChatterjeeCorpWatch Blog
February 3rd, 2014
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines “for western patients who can afford it” not for the “Indian market.” The company has been critical of the Indian governments efforts to make cheap generic drugs available locally.

Bumper Year for Corporate Donations Reveals Profit Motives
by Rick CohenCorpWatch Blog
September 10th, 2013
U.S. corporations gave away $18.15 billion in charitable donations in 2012 – a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.